BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Filippi R, Lombardi P, Quarà V, Fenocchio E, Aimar G, Milanesio M, Leone F, Aglietta M. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. Expert Opin Pharmacother 2019;20:2121-37. [PMID: 31550186 DOI: 10.1080/14656566.2019.1667335] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Wu CE, Pan YR, Yeh CN, Lunec J. Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers. Biomolecules 2020;10:E1474. [PMID: 33113997 DOI: 10.3390/biom10111474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Wu CE, Chou WC, Hsieh CH, Chang JW, Lin CY, Yeh CN, Chen JS. Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience. BMC Cancer 2020;20:422. [PMID: 32410631 DOI: 10.1186/s12885-020-06914-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
3 Oneda E, Abu Hilal M, Zaniboni A. Biliary Tract Cancer: Current Medical Treatment Strategies.Cancers (Basel). 2020;12. [PMID: 32423017 DOI: 10.3390/cancers12051237] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
4 Filippi R, Leone F, Fornaro L, Aprile G, Casadei-Gardini A, Silvestris N, Palloni A, Satolli MA, Scartozzi M, Russano M, Lutrino SE, Lombardi P, Frega G, Garattini SK, Vivaldi C, Spadi R, Giulia O, Fenocchio E, Brunetti O, Aglietta M, Brandi G. Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. J Chemother 2021;:1-10. [PMID: 34313188 DOI: 10.1080/1120009X.2021.1953887] [Reference Citation Analysis]
5 Ulusakarya A, Karaboué A, Ciacio O, Pittau G, Haydar M, Biondani P, Gumus Y, Chebib A, Almohamad W, Innominato PF. A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. BMC Cancer 2020;20:515. [PMID: 32493242 DOI: 10.1186/s12885-020-07004-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Zhang W, Shi J, Wang Y, Zhou H, Zhang Z, Han Z, Li G, Yang B, Cao G, Ke Y, Zhang T, Song T, QiangLi. Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers. Cancer Immunol Immunother 2021;70:1001-14. [PMID: 33095329 DOI: 10.1007/s00262-020-02745-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Rizzo A, Ricci AD, Tavolari S, Brandi G. Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives. Cancer Genomics Proteomics. 2020;17:441-452. [PMID: 32859625 DOI: 10.21873/cgp.20203] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 38.0] [Reference Citation Analysis]